Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KIF11 | P52732 | 10/20 | 0.48 |
| ▸ | CYBB | P04839 | 1/20 | 0.48 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.48 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.48 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629024 | 0.91 | KIF11 (0.47) | HDAC1HDAC8HDAC6MAPTKIF11 | |
| SCHEMBL10651353 | 0.84 | KIF11 (0.58) | MAPTKIF11CYBBNOX3NOX4 | |
| SCHEMBL4596143 | 0.81 | KIF11 (0.66) | HDAC1HDAC8HDAC6MAPTKIF11 | |
| SCHEMBL5507140 | 0.80 | HDAC1 (0.57) | HDAC1HDAC8HDAC6MAPTTP53 | |
| SCHEMBL11243199 | 0.77 | HDAC1 (0.45) | HDAC1HDAC8HDAC6MAPTKIF11 | |
| SCHEMBL8853550 | 0.76 | HDAC1 (0.57) | HDAC1HDAC8HDAC6MAPTNOX1 | |
| SCHEMBL5638460 | 0.76 | KMT2A (0.62) | HDAC1HDAC8HDAC6MAPTTP53 | |
| SCHEMBL10075537 | 0.76 | HDAC1 (0.53) | HDAC1HDAC8HDAC6MAPTTP53 | |
| SCHEMBL12302659 | 0.76 | HDAC1 (0.53) | HDAC1HDAC8HDAC6MAPTNOX1 | |
| SCHEMBL30806264 | 0.76 | KIF11 (0.62) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012050227-A1 | PEPTIDE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | WO | disclosed |
| US-20120094898-A1 | PEPTIDE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094899-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2206721-A1 | NEUROMEDIN U DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-0657407-B1 | Process for the preparation of 3-fluoro-4,6-dichlorotoluene | BAYER AG (DE) | 1997-12-10 | — | — | EP | disclosed |
| EP-0657407-A1 | Process for the preparation of 3-fluoro-4,6-dichlorotoluene | BAYER AG (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0292824-B1 | PROCESS FOR THE NUCLEAR CHLORINATION OF AROMATIC HYDROCARBONS | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
| US-4851596-A | Process for nucleus-chlorination of aromatic hydrocarbons | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | NMUR1, NMUR2, NMBR | HDAC1 4807/4885HDAC8 4674/4885HDAC6 3652/4885 |
| US-20120094899-A1 | NEUROMEDIN U DERIVATIVE | NMUR1, NMUR2, NMBR | HDAC1 4760/4885HDAC8 4675/4885HDAC6 4336/4885 |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | GNRHR, SHBG, LHCGR | HDAC1 1536/4885HDAC8 1702/4885HDAC6 1629/4885 |
| US-20120094898-A1 | PEPTIDE DERIVATIVE | NPPA, LNPEP, NGLY1 | HDAC1 3040/4885HDAC8 2631/4885HDAC6 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.